Abstract
A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.
MeSH terms
-
Animals
-
Antibodies / immunology
-
Antibodies / therapeutic use*
-
Antibodies, Bispecific / therapeutic use
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm / immunology
-
Antibodies, Neoplasm / therapeutic use
-
Antibody-Dependent Cell Cytotoxicity
-
Antigens, Neoplasm / immunology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Combined Modality Therapy
-
Cytokines / administration & dosage
-
Cytokines / therapeutic use
-
Drug Delivery Systems
-
Humans
-
Immunization, Passive
-
Immunoconjugates / therapeutic use
-
Immunotherapy / methods
-
Immunotoxins / therapeutic use
-
Liposomes
-
Mice
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / immunology
-
Neoplasm, Residual
-
Neoplasms / drug therapy
-
Neoplasms / immunology
-
Neoplasms / pathology
-
Neoplasms / radiotherapy
-
Neoplasms / therapy*
-
Neovascularization, Pathologic / immunology
-
Neovascularization, Pathologic / therapy
-
Prodrugs / administration & dosage
-
Protein Engineering
-
Radioimmunotherapy
-
Recombinant Fusion Proteins / immunology
-
Recombinant Fusion Proteins / therapeutic use
-
Rituximab
-
Trastuzumab
-
Treatment Outcome
-
Xenograft Model Antitumor Assays
Substances
-
Antibodies
-
Antibodies, Bispecific
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm
-
Antigens, Neoplasm
-
Cytokines
-
Immunoconjugates
-
Immunotoxins
-
Liposomes
-
Neoplasm Proteins
-
Prodrugs
-
Recombinant Fusion Proteins
-
Rituximab
-
Trastuzumab